



(11) **EP 3 242 681 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(51) Int Cl.:  
**A61K 38/57 (2006.01)**

(86) International application number:  
**PCT/EP2016/050100**

(48) Corrigendum issued on:  
**25.11.2020 Bulletin 2020/48**

(87) International publication number:  
**WO 2016/110496 (14.07.2016 Gazette 2016/28)**

(45) Date of publication and mention  
of the grant of the patent:  
**08.07.2020 Bulletin 2020/28**

(21) Application number: **16700150.2**

(22) Date of filing: **06.01.2016**

(54) **NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER**

NEUARTIGE VERBINDUNGEN ZUR KREBSBEHANDLUNG

NOUVEAUX COMPOSÉS POUR LE TRAITEMENT DU CANCER

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB**  
**GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO**  
**PL PT RO RS SE SI SK SM TR**

(30) Priority: **06.01.2015 EP 15150219**

(43) Date of publication of application:  
**15.11.2017 Bulletin 2017/46**

(73) Proprietor: **QITHERA GmbH**  
**52525 Heinsberg (DE)**

(72) Inventors:  
• **DAHL, Edgar**  
**4721 Kelmis (BE)**  
• **ROSE, Michael**  
**52134 Herzogenrath (DE)**  
• **HUTH, Sebastian**  
**52080 Aachen (DE)**

(74) Representative: **Roth, Andy Stefan**  
**Dr. Roth Patentanwaltskanzlei**  
**Kaistrasse 5**  
**40221 Düsseldorf (DE)**

(56) References cited:  
**WO-A1-2013/135836 US-A1- 2002 132 981**

- **VALENZUELA DET AL: "Human secreted protein encoded by DNA clone vo33 1", GENESEQ., 21 September 2000 (2000-09-21), XP002740580, [retrieved on 2001-01-26] & WO 00/55375 A1 (ALPHAGENE INC [US]) 21 September 2000 (2000-09-21)**
- **"Human protein modification and maintenance molecule (PMMM) protein #1", GENESEQ., 4 December 2003 (2003-12-04), XP002740591, [retrieved on 2004-04-22] & WO 03/100016 A2 (INCYTE CORP [US]; KHARE REENA [US]; BULLOCH SEAN A) 4 December 2003 (2003-12-04)**
- **KLOTEN VERA ET AL: "Epigenetic inactivation of the novel candidate tumor suppressor gene ITIH5 in colon cancer predicts unfavorable overall survival in the CpG island methylator phenotype", EPIGENETICS, LANDES BIOSCIENCE, US, vol. 9, no. 9, 1 September 2014 (2014-09-01), pages 1290-1301, XP002740582, ISSN: 1559-2294 [retrieved on 2014-08-04]**

**EP 3 242 681 B8**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- ROSE MICHAEL ET AL: "Epigenetic inactivation of ITIH5 promotes bladder cancer progression and predicts early relapse of pT1 high-grade urothelial tumours", **CARCINOGENESIS**, OXFORD UNIVERSITY PRESS, GB, vol. 35, no. 3, 1 March 2014 (2014-03-01), pages 727-736, XP002740583, ISSN: 0143-3334, DOI: 10.1093/CARCIN/BGT375 [retrieved on 2013-11-21]
- MICHAEL ROSE: "Identifizierung und Validierung neuer DNA-Methylungsbiomarker zur Früherkennung von Harnblasentumoren sowie Charakterisierung des putativen Tumorsuppressorgens ITIH5 für das Harnblasen- und Mammakarzinom", **INTERNET CITATION**, 13 May 2013 (2013-05-13), pages 3PP.I-XIV, XP002740584, Retrieved from the Internet: URL:<http://publications.rwth-aachen.de/record/229798/files/4573.pdf> [retrieved on 2015-06-03]